References
- Wu G, Doberstein SK. HTS technologies in biopharmaceutical discovery. Drug Discov Today. 2006;11:718–15. doi:https://doi.org/10.1016/j.drudis.2006.06.010.
- Sundberg SA. High-throughput and ultra-high-throughput screening: solution- and cell-based approaches. Curr Opin Biotechnol. 2000;11:47–53. doi:https://doi.org/10.1016/S0958-1669(99)00051-8.
- Fox S, Farr-Jones S, Sopchak L, Boggs A, Nicely HW, Khoury R, Biros M. High-throughput screening: update on practices and success. J Biomol Screen. 2006;11:864–69. doi:https://doi.org/10.1177/1087057106292473.
- Mayr LM, Bojanic D. Novel trends in high-throughput screening. Curr Opin Pharmacol. 2009;9:580–88. doi:https://doi.org/10.1016/j.coph.2009.08.004.
- Bleicher KH, Böhm HJ, Müller K, Alanine AI. Hit and lead generation: beyond high-throughput screening. Nat Rev Drug Discov. 2003;2:369–78. doi:https://doi.org/10.1038/nrd1086.
- Sedykh SE, Prinz VV, Buneva VN, Nevinsky GA. Bispecific antibodies: design, therapy, perspectives. Drug Des Devel Ther. 2018;12:195–208. doi:https://doi.org/10.2147/DDDT.
- Carter PJ, Lazar GA. Next generation antibody drugs: pursuit of the ‘high-hanging fruit’. Nat Rev Drug Discov. 2018;17:197–223. doi:https://doi.org/10.1038/nrd.2017.227.
- Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18:585–608. doi:https://doi.org/10.1038/s41573-019-0028-1.
- Knight T, Callaghan MU. The role of emicizumab, a bispecific factor IXa- and factor X- directed antibody, for the prevention of bleeding episodes in patients with hemophilia A. Ther Adv Vaccines. 2017;5:39–47. doi:https://doi.org/10.1177/2051013617693753.
- Chames P, van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. 2009;157:220–33. doi:https://doi.org/10.1111/j.1476-5381.2009.00190.x.
- Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discov Today. 2015;20:838–47. doi:https://doi.org/10.1016/j.drudis.2015.02.008.
- Mazor Y, Hansen A, Yang C, Chowdhury PS, Wang J, Stephens G, Wu H, Dall´Acqua WF. Insights into the molecular basis of a bispecific antibody’s target selectivity. mAbs. 2015;7:461–69. doi:https://doi.org/10.1080/19420862.2015.1022695.
- Sellmann C, Doerner A, Knuehl C, Rasche N, Sood V, Krah S, Rhiel L, Messemer A, Wesolowski J, Schuette M, et al. Balancing selectivity and efficacy of bispecific epidermal growth factor receptor (EGFR) × c-MET antibodies and antibody-drug conjugates. J Biol Chem. 2016;291:25106–19. doi:https://doi.org/10.1074/jbc.M116.753491.
- Husain B, Ellerman D. Expanding the boundaries of biotherapeutics with bispecific antibodies. BioDrugs. 2018;32:441–64. doi:https://doi.org/10.1007/s40259-018-0299-9.
- Klein C, Schaefer W, Regula JT, Dumontet C, Brinkmann U, Bacac M, Umaña P. Engineering therapeutic bispecific antibodies using CrossMab technology. Methods. 2019;154:21–31. doi:https://doi.org/10.1016/j.ymeth.2018.11.008.
- Davis JH, Aperlo C, Li Y, Kurosawa E, Lan Y, Lo KM, Huston JS. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng Des Sel. 2010;23:195–202. doi:https://doi.org/10.1093/protein/gzp094.
- Scott MJ, Lee JA, Wake MS, Batt KV, Wattam TA, Hiles ID, Batuwangala TD, Ashman CI, Steward M. ‘In-Format’ screening of a novel bispecific antibody format reveals significant potency improvements relative to unformatted molecules. mAbs. 2017;9:85–93. doi:https://doi.org/10.1080/19420862.2016.1249078.
- Desjarlais JR, Lazar GA. Modulation of antibody effector function. Exp Cell Res. 2011;317:1278–85. doi:https://doi.org/10.1016/j.yexcr.2011.03.018.
- Mazor Y, Sachsenmeier KF, Yang C, Hansen A, Filderman J, Mulgrew K, Wu H, Dall´Acqua WF. Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence. Sci Rep. 2017;7:1–11. doi:https://doi.org/10.1038/srep40098.
- Xiao X, Douthwaite JA, Chen Y, Kemp B, Kidd S, Percival-Alwyn J, Smith A, Goode K, Swerdlow B, Lowe D, et al. A high-throughput platform for population reformatting and mammalian expression of phage display libraries to enable functional screening as full-length IgG. mAbs. 2017;9:996–1006. doi:https://doi.org/10.1080/19420862.2017.1337617.
- Labrijn AF, Meesters JI, de Goeij BE, van den Bremer ET, Neijssen J, van Kampen MD, Strumane K, Verploegen S, Kundu A, Gramer MJ, et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci. 2013;110:5145–50. doi:https://doi.org/10.1073/pnas.1220145110.
- Han L, Chen J, Ding K, Zong H, Xie Y, Jiang H, Zhang B, Lu H, Yin W, Gilly J, et al. Efficient generation of bispecific IgG antibodies by split intein mediated protein trans-splicing system. Sci Rep. 2017;7:8360. doi:https://doi.org/10.1038/s41598-017-08641-3.
- Han L, Zong H, Zhou Y, Pan Z, Chen J, Ding K, Xie Y, Jiang H, Zhang B, Lu H, et al. Naturally split intein Npu DnaE mediated rapid generation of bispecific IgG antibodies. Methods. 2019;154:32–37. doi:https://doi.org/10.1016/j.ymeth.2018.10.001.
- Badalà F, Nouri-mahdavi K, Raoof DA. Inteins: nature´s gift to protein chemists. Comput Long Beach Calif. 2008;144:724–32.
- Vila-Perelló M, Liu Z, Shah NH, Willis JA, Idoyaga J, Muir TW. Streamlined expressed protein ligation using split inteins. J Am Chem Soc. 2013;135:286–92. doi:https://doi.org/10.1021/ja309126m.
- Wood DW, Camarero JA. Intein applications: from protein purification and labeling to metabolic control methods. J Biol Chem. 2014;289:14512–19. doi:https://doi.org/10.1074/jbc.R114.552653.
- Guan D, Ramirez M, Chen Z. Split intein mediated ultra-rapid purification of tagless protein (SIRP). Biotechnol Bioeng. 2013;110:2471–81. doi:https://doi.org/10.1002/bit.v110.9.
- Shah NH, Eryilmaz E, Cowburn D, Muir TW. Extein residues play an intimate role in the rate-limiting step of protein trans -splicing. J Am Chem Soc. 2013;135:5839–47. doi:https://doi.org/10.1021/ja401015p.
- Carvajal-vallejos P, Pallissé R, Mootz HD, Schmidt SR. Unprecedented rates and efficiencies revealed for new natural split inteins from metagenomic sources. J Biol Chem. 2012;287:28686–96. doi:https://doi.org/10.1074/jbc.M112.372680.
- Brezski RJ, Jordan RE. Cleavage of IgGs by proteases associated with invasive diseases: an evasion tactic against host immunity? mAbs. 2010;2:212–20. doi:https://doi.org/10.4161/mabs.2.3.11780.
- Moritz B, Stracke JO. Assessment of disulfide and hinge modifications in monoclonal antibodies. Electrophoresis. 2017;38:769–85. doi:https://doi.org/10.1002/elps.201600425.
- Zettler J, Schütz V, Mootz HD. The naturally split Npu DnaE intein exhibits an extraordinarily high rate in the protein trans-splicing reaction. FEBS Lett. 2009;583:909–14. doi:https://doi.org/10.1016/j.febslet.2009.02.003.
- Krah S, Schröter C, Eller C, Riehl L, Rasche N, Beck J, Sellmann C, Günther R, Toleikis L, Hock B, et al. Generation of human bispecific common light chain antibodies by combining animal immunization and yeast display. Protein Eng Des Sel. 2017;30:291–301. doi:https://doi.org/10.1093/protein/gzw077.
- Sampei Z, Igawa T, Soeda T, Okuyama-Nishida Y, Moriyama C, Wakabayashi T, Tanaka E, Muto A, Kojima T, Kitazawa T, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One. 2013;8:e57479. doi:https://doi.org/10.1371/journal.pone.0057479.
- Kitazawa T, Igawa T, Sampei Z, Muto A, Kojima T, Soeda T, Yoshihashi K, Okuyama-Nishida Y, Saito H, Tsunoda H, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia a model. Nat Med. 2012;18:1570–74. doi:https://doi.org/10.1038/nm.2942.
- Xu Y, Lee J, Tran C, Heibeck TH, Wang WD, Yang J, Stafford RL, Steiner AR, Sato AK, Hallam TJ, et al. Production of bispecific antibodies in ‘knobs-into-holes’ using a cell-free expression system. mAbs. 2015;7:231–42. doi:https://doi.org/10.4161/19420862.2015.989013.
- Vivier E, Nunès JA, Vély F. Natural killer cell signaling pathways. Science. 2004;306:1517–19. doi:https://doi.org/10.1126/science.1103478.
- Pahl J, Cerwenka A. Tricking the balance: NK cells in anti-cancer immunity. Immunobiology. 2017;222:11–20. doi:https://doi.org/10.1016/j.imbio.2015.07.012.
- Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2009;69:4941–44. doi:https://doi.org/10.1158/0008-5472.CAN-09-0547.
- Bluemel C, Hausmann S, Fluhr P, Sriskandarajah M, Stallcup WB, Baeuerle PA, Kufer P. Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen. Cancer Immunol ImmunoTher. 2010;59:1197–209. doi:https://doi.org/10.1007/s00262-010-0844-y.
- Yumura K, Akiba H, Nagatoishi S, Kusano-Arai O, Iwanari H, Hamakubo T, Tsumoto K. Use of SpyTag/SpyCatcher to construct bispecific antibodies that target two epitopes of a single antigen. J Biochem. 2017;3:203–10. doi:https://doi.org/10.1093/jb/mvx023.
- Sutherland AR, Alam MK, Geyer CR. Post-translational assembly of protein parts into complex devices by using spytag/spycatcher protein ligase. ChemBioChem. 2019;20:319–28. doi:https://doi.org/10.1002/cbic.v20.3.
- Brinkmann U, Kontermann RE. The making of bispecific antibodies. mAbs. 2017;9:182–212. doi:https://doi.org/10.1080/19420862.2016.1268307.
- Garber K. Bispecific antibodies rise again. Nat Rev Drug Discov. 2014;13:799–801. doi:https://doi.org/10.1038/nrd4478.
- Bhagawati M, Terhorst TME, Füsser F, Hoffmann S, Pasch T. A mesophilic cysteine-less split intein for protein trans - splicing applications under oxidizing conditions. PNAS. 2019;44:22164–72. doi:https://doi.org/10.1073/pnas.1909825116.
- Stevens AJ, Brown ZZ, Shah NH, Sekar G, Cowburn D, Muir TW. Design of a split intein with exceptional protein splicing activity. J Am Chem Soc. 2016;138:2162–65. doi:https://doi.org/10.1021/jacs.5b13528.